DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Obinutuzumab is an investigational drug.
There have been 129 clinical trials for Obinutuzumab. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2016.
The most common disease conditions in clinical trials are Lymphoma, Leukemia, Lymphoid, and Leukemia, Lymphocytic, Chronic, B-Cell. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and National Cancer Institute (NCI).
There are twenty-four US patents protecting this investigational drug and nine hundred and forty international patents.
Recent Clinical Trials for Obinutuzumab
|Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma||Genentech, Inc.||Phase 2|
|Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma||Emory University||Phase 2|
|Venetoclax and Obinutuzumab for Relapsed Primary CNS Lymphoma||University Hospital Freiburg||Phase 1|
Top disease conditions for Obinutuzumab
Top clinical trial sponsors for Obinutuzumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Obinutuzumab||Start Trial||Antibody targeting cell surface deposited complement protein C3d and use thereof||The United States of America, as represented by the Secretary, Department of Health and Human Services (Washington, DC) University of Virginia Patent Foundation (Charlottesville, VA)||Start Trial|
|Obinutuzumab||Start Trial||Salts and solid form of a BTK inhibitor||PRINCIPIA BIOPHARMA INC. (South San Francisco, CA)||Start Trial|
|Obinutuzumab||Start Trial||Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione||Celgene Corporation (Summit, NJ)||Start Trial|
|Obinutuzumab||Start Trial||Mesalamine for the treatment of cancer||Cipla Limited (Mumbai, IN)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Obinutuzumab||European Patent Office||3092252||2034-01-08||Start Trial|
|Obinutuzumab||World Intellectual Property Organization (WIPO)||2015105973||2034-01-08||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|